ArticleGlobal spine journal2026
The Use of Recombinant Bone Morphogenetic Protein-2 in the Treatment of Spondylodiscitis.
Article in Global spine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Study DesignRetrospective observational cohort.ObjectiveAlthough recombinant human bone morphogenetic protein-2 (rhBMP-2) has been shown to enhance fusion rates in spinal fusion surgery, its use in patients with spondylodiscitis remains controversial. This study evaluated the surgical outcomes and complication rates associated with rhBMP-2 use in the treatment of spondylodiscitis.MethodsWe retrospectively reviewed a consecutive series of patients who underwent surgical treatment for spondylodiscitis, including anterior column debridement and reconstruction with cage placement, with at least 12-month follow-up. Outcomes and complications were compared between patients who received rhBMP-2 and those who did not.ResultsA total of 133 patients (mean follow-up, 32.4 ± 27.4 months) were included; 114 (86%) received rhBMP-2 (mean dose, 14.4 ± 6.4 mg), anteriorly in 97 (73%), posteriorly in 92 (69%), and in both locations in 75 patients (56%). . The fusion rate was significantly higher in BMP_Posterior vs non-BMP_Posterior (95% vs 80%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.